1. From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
   Giuseppe A. Palumbo et al, 2021, Frontiers in Oncology CrossRef
2. Iron overload in patients with myelodysplastic syndromes: An updated overview
   Nour M. Moukalled et al, 2018, Cancer CrossRef
3. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation
   N Jaekel et al, 2016, Bone Marrow Transplantation CrossRef
4. Too much iron: A masked foe for leukemias
   Eolia Brissot et al, 2020, Blood Reviews CrossRef
5. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
   Amer M. Zeidan et al, 2017, Critical Reviews in Oncology/Hematology CrossRef
6. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
   Heather A. Leitch et al, 2018, Leukemia Research CrossRef
7. Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata
   Luca Maurillo et al, 2015, European Journal of Haematology CrossRef
8. Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study
   Pellegrino Musto et al, 2017, British Journal of Haematology CrossRef
9. New insights into transfusion-related iron toxicity: Implications for the oncologist
   John B. Porter et al, 2016, Critical Reviews in Oncology/Hematology CrossRef
10. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years
    Jonathan Feld et al, 2020, Expert Review of Anticancer Therapy CrossRef
11. Clinical Efficacy of Chelation Therapy in Patients with Low-Risk Myelodysplastic Syndrome
    Sergei Vasil'evich Gritsaev et al, 2019, Clinical oncohematology CrossRef
12. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
    Nicole Carreau et al, 2016, Blood Reviews CrossRef
13. To chelate or not to chelate in MDS: That is the question!
    Amer M. Zeidan et al, 2018, Blood Reviews CrossRef
14. Metal Antagonists
    Joshua P. Gray et al, 2015, A worldwide yearly survey of new data in adverse drug reactions CrossRef
15. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
    Niraj Shenoy et al, 2014, Blood CrossRef
16. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate
    Farhan Imran et al, 2017, Expert Review of Hematology CrossRef
17. Iron toxicity – Its effect on the bone marrow
    Alessandro Isidori et al, 2018, Blood Reviews CrossRef